(Q34125408)

31 July 2017

1 reference

title

Nonhypoglycemic drug reactions of agents used to treat diabetes (English)

1 reference

31 July 2017

White JA

1

1 reference

31 July 2017

Hirsch IB

series ordinal

2

1 reference

31 July 2017

publication date

1 December 2000

1 reference

Endocrinology and Metabolism Clinics of North America

31 July 2017

published in

1 reference

31 July 2017

volume

29

1 reference

31 July 2017

issue

4

1 reference

31 July 2017

page(s)

803-811

1 reference

Hepatocellular injury in a patient receiving rosiglitazone. A case report

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970165-1

7 January 2021

Acarbose-associated hepatotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970165-1

7 January 2021

Hepatic injury caused by acarbose

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970165-1

7 January 2021

The sulfonylurea controversy: more questions from the heart

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970165-1

7 January 2021

Acarbose-induced acute severe hepatotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970165-1

7 January 2021

The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970165-1

7 January 2021

Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970165-1

7 January 2021

Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970165-1

7 January 2021

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970165-1

7 January 2021

Acarbose-induced acute hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970165-1

7 January 2021

Ephedrine: a new treatment for diabetic neuropathic oedema

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970165-1

7 January 2021

Hepatic failure in a patient taking rosiglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970165-1

7 January 2021

Acarbose-induced hepatic injury

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970165-1

7 January 2021

Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970165-1

7 January 2021

Significant weight gain with rezulin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970165-1

7 January 2021

Pulmonary edema associated with troglitazone therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970165-1

7 January 2021

Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970165-1

7 January 2021

Comparative tolerability profiles of oral antidiabetic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970165-1

7 January 2021

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970165-1

7 January 2021

Ileus: a rare side effect of acarbose

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970165-1

7 January 2021

Potentially lethal ileus associated with acarbose treatment for NIDDM

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970165-1

7 January 2021

Adverse effects of exogenous insulin. Clinical features, management and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970165-1

7 January 2021

"Glitazones", a prospect for non-insulin-dependent diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970165-1

7 January 2021

The renal metabolism of insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970165-1

7 January 2021

A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970165-1

7 January 2021

Insulin-induced cardiac failure

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970165-1

7 January 2021

Effect of thiazolidinediones on expression of UCP2 and adipocyte markers in human PAZ6 adipocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970165-1

7 January 2021

10.1016/S0889-8529(05)70165-1

Identifiers

DOI

1 reference

31 July 2017

1 reference